Search: id:"swepub:oai:gup.ub.gu.se/286418" >
Efficacy of alemtuz...
-
Van Wijmeersch, B.
(author)
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
- Article/chapterEnglish2020
Publisher, publication year, extent ...
-
2019-11-01
-
SAGE Publications,2020
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/286418
-
https://gup.ub.gu.se/publication/286418URI
-
https://doi.org/10.1177/1352458519881759DOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background:Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. Objective: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers). Methods:Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension. Results:Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1-2 years pre-alemtuzumab and higher mean baseline Expanded Disability Status Scale score than patients without relapse. Their annualized relapse rate declined from Year 1 (CARE-MS I: 1.3; CARE-MS II: 1.2) to Year 2 following Course 2 (0.3; 0.5) and remained low thereafter. Over 6 years, 60% remained free of 6-month confirmed disability worsening; 24% (CARE-MS I) and 34% (CARE-MS II) achieved 6-month confirmed disability improvement. During Year 6, 69% (CARE-MS I) and 68% (CARE-MS II) were free of magnetic resonance imaging (MRI) disease activity. Median percent yearly brain volume loss (Year 1: -0.67% (CARE-MS I); -0.47% (CARE-MS II)) declined after Course 2 (Year 6: -0.24%; -0.13%). Conclusion: Early relapsers' outcomes improved after completing the second alemtuzumab course. These findings support administering the approved two-course regimen to maximize clinical benefit. ClinicalTrials.gov registration numbers:CARE-MS I, II, extension: NCT00530348, NCT00548405, NCT00930553.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Singer, B. A.
(author)
-
Boster, A.
(author)
-
Broadley, S.
(author)
-
Fernandez, O.
(author)
-
Freedman, M. S.
(author)
-
Izquierdo, G.
(author)
-
Lycke, Jan,1956Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology(Swepub:gu)xlycja
(author)
-
Pozzilli, C.
(author)
-
Sharrack, B.
(author)
-
Steingo, B.
(author)
-
Wiendl, H.
(author)
-
Wray, S.
(author)
-
Ziemssen, T.
(author)
-
Chung, L.
(author)
-
Margolin, D. H.
(author)
-
Thangavelu, K.
(author)
-
Vermersch, P.
(author)
-
Göteborgs universitetInstitutionen för neurovetenskap och fysiologi
(creator_code:org_t)
Related titles
-
In:Multiple Sclerosis Journal: SAGE Publications26:13, s. 1719-17281352-45851477-0970
Internet link
Find in a library
To the university's database
- By the author/editor
-
Van Wijmeersch, ...
-
Singer, B. A.
-
Boster, A.
-
Broadley, S.
-
Fernandez, O.
-
Freedman, M. S.
-
show more...
-
Izquierdo, G.
-
Lycke, Jan, 1956
-
Pozzilli, C.
-
Sharrack, B.
-
Steingo, B.
-
Wiendl, H.
-
Wray, S.
-
Ziemssen, T.
-
Chung, L.
-
Margolin, D. H.
-
Thangavelu, K.
-
Vermersch, P.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Multiple Scleros ...
- By the university
-
University of Gothenburg